Role of phosphoproteomics in the development of personalized cancer therapies

Proteomics - Clinical Applications

Volumn 9, Issue 3-4, 2015, Pages 383-395

  Cutillas, Pedro R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Mass spectrometry; Network biology; Precision medicine; Systems biology

Indexed keywords

B RAF KINASE; BCR ABL PROTEIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOPROTEIN; PROTEIN KINASE B; SORAFENIB; TRASTUZUMAB; VEMURAFENIB; PHOSPHOPEPTIDE;

BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; DRUG RESPONSE; GENE MUTATION; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MELANOMA; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; ONCOGENE; PERSONALIZED MEDICINE; PHOSPHOPROTEOMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR MICROENVIRONMENT; METABOLISM; NEOPLASM; PROCEDURES; SYSTEMS BIOLOGY;

HUMANS; MASS SPECTROMETRY; NEOPLASMS; PHOSPHOPEPTIDES; PHOSPHOPROTEINS; PRECISION MEDICINE; PROTEOMICS; SYSTEMS BIOLOGY;

EID: 84928055838     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400104     Document Type: Review

References (93)

1. Roux, P. P., Thibault, P., The coming of age of phosphoproteomics-from large data sets to inference of protein functions. Mol. Cell. Proteomics 2013, 12, 3453-3464.
2. Liu, Z., Wang, Y., Xue, Y., Phosphoproteomics-based network medicine. FEBS J. 2013, 280, 5696-5704.
3. Stasyk, T., Huber, L. A., Mapping in vivo signal transduction defects by phosphoproteomics. Trends Mol. Med. 2012, 18, 43-51.
4. Cutillas, P. R., Jorgensen, C., Biological signalling activity measurements using mass spectrometry. Biochem. J. 2011, 434, 189-199.
5. Haley, J., White, F. M., Adaptive protein and phosphoprotein networks which promote therapeutic sensitivity or acquired resistance. Biochem. Soc. Trans. 2014, 42, 758-764.
6. Wilkes, E. H., Casado, P., Cutillas, P. R., Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies. Biochem. Soc. Trans. 2014, 42, 791-797.
7. Dar, A. C., Shokat, K. M., The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Ann. Rev. Biochem. 2011, 80, 769-795.
8. Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M. et al., Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99, 3530-3539.
9. Sawyers, C. L., Shifting paradigms: the seeds of oncogene addiction. Nat. Med. 2009, 15, 1158-1161.
10. Hanahan, D., Weinberg, R. A., Hallmarks of cancer: the next generation. Cell 2011, 144, 646-674.
11. Bachman, K. E., Argani, P., Samuels, Y., Silliman, N. et al., The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 2004, 3, 772-775.
12. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N. et al., High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304, 554.
13. Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. et al., NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68, 8022-8030.
14. Brose, M. S., Volpe, P., Feldman, M., Kumar, M. et al., BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002, 62, 6997-7000.
15. Davies, H., Bignell, G. R., Cox, C., Stephens, P. et al., Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949-954.
16. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B. et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364, 2507-2516.
17. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H. et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361, 947-957.
18. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S. et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
19. Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E. et al., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372, 449-456.
20. Gonzalez de Castro, D., Clarke, P. A., Al-Lazikani, B., Workman, P., Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin. Pharmacol. Ther. 2013, 93, 252-259.
21. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C. et al., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20, 719-726.
22. Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E. et al., Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J.Med. 2009, 361, 1058-1066.
23. Bozic, I., Antal, T., Ohtsuki, H., Carter, H. et al., Accumulation of driver and passenger mutations during tumor progression. Proc. Natl. Acad. Sci. USA 2010, 107, 18545-18550.
24. Davies, H., Hunter, C., Smith, R., Stephens, P. et al., Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005, 65, 7591-7595.
25. Workman, P., Clarke, P. A., Raynaud, F. I., van Montfort, R. L., Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010, 70, 2146-2157.
26. Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F. et al., Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 2008, 8, 393-412.
27. Dan, S., Okamura, M., Seki, M., Yamazaki, K. et al., Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res. 2010, 70, 4982-4994.
28. Alcolea, M. P., Casado, P., Rodriguez-Prados, J. C., Vanhaesebroeck, B., Cutillas, P. R., Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol. Cell. Proteomics 2012, 11, 453-466.
29. Casado, P., Alcolea, M. P., Iorio, F., Rodriguez-Prados, J. C. et al., Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol. 2013, 14, R37.
30. Janku, F., Wheler, J. J., Westin, S. N., Moulder, S. L. et al., PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol. 2012, 30, 777-782.
31. Klempner, S. J., Myers, A. P., Cantley, L. C., What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov. 2013, 3, 1345-1354.
32. Robin, X., Creixell, P., Radetskaya, O., Santini, C. C. et al., Personalized network-based treatments in oncology. Clin. Pharmacol. Ther. 2013, 94, 646-650.
33. Elkabets, M., Vora, S., Juric, D., Morse, N. et al., mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer. Sci. Trans. Med. 2013, 5, 196ra199.
34. Cancer Genome Atlas Research, N., Weinstein, J. N., Collisson, E. A., Mills, G. B. et al., The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013, 45, 1113-1120.
35. Forbes, S. A., Bindal, N., Bamford, S., Cole, C. et al., COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011, 39, D945-D950.
36. Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D. et al., Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483, 570-575.
37. Blau, C. A., Liakopoulou, E., Can we deconstruct cancer, one patient at a time? Trends Genet. 2013, 29, 6-10.
38. Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S. et al., A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012, 150, 165-178.
39. Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M. et al., Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487, 500-504.
40. Zeng, Z., Shi, Y. X., Samudio, I. J., Wang, R. Y. et al., Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 113, 6215-6224.
41. Rajeeve, V., Vendrell, I., Wilkes, E., Torbett, N., Cutillas, P. R., Cross-species proteomics reveals specific modulation of signaling in cancer and stromal cells by phosphoinositide 3-kinase (PI3K) inhibitors. Mol. Cell. Proteomics 2014, 13, 1457-1470.
42. Damia, G., Garattini, S., The pharmacological point of view of resistance to therapy in tumors. Cancer Treatment Rev. 2014, 40, 909-916.
43. Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R. et al., Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013, 494, 251-255.
44. Knoechel, B., Roderick, J. E., Williamson, K. E., Zhu, J. et al., An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat. Genet. 2014, 46, 364-370.
45. Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P. et al., A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141, 69-80.
46. Bertacchini, J., Guida, M., Accordi, B., Mediani, L. et al., Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. Leukemia 2014, 28, 2197-2205.
47. Bertotti, A., Burbridge, M. F., Gastaldi, S., Galimi, F. et al., Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci. Signal. 2009, 2, er11.
48. Cutillas, P. R., Khwaja, A., Graupera, M., Pearce, W. et al., Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. Proc. Natl. Acad. Sci. USA 2006, 103, 8959-8964.
49. Greis, K. D., Mass spectrometry for enzyme assays and inhibitor screening: an emerging application in pharmaceutical research. Mass Spectrom. Rev. 2007, 26, 324-339.
50. Patricelli, M. P., Szardenings, A. K., Liyanage, M., Nomanbhoy, T. K. et al., Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 2007, 46, 350-358.
51. Stuhlmiller, T. J., Earp, H. S., Johnson, G. L., Adaptive reprogramming of the breast cancer kinome. Clin. Pharmacol. Ther. 2014, 95, 413-415.
52. McAllister, F. E., Niepel, M., Haas, W., Huttlin, E. et al., Mass spectrometry based method to increase throughput for kinome analyses using ATP probes. Anal. Chem. 2013, 85, 4666-4674.
53. Bensimon, A., Heck, A. J., Aebersold, R., Mass spectrometry-based proteomics and network biology. Ann. Rev. Biochem. 2012, 81, 379-405.
54. Terfve, C., Saez-Rodriguez, J., Modeling signaling networks using high-throughput phospho-proteomics. Adv. Exp. Med. Biol. 2012, 736, 19-57.
55. Iliuk, A. B., Tao, W. A., Is phosphoproteomics ready for clinical research? Clin. Chim. Acta 2013, 420, 23-27.
56. Stehle, F., Schulz, K., Seliger, B., Towards defining biomarkers indicating resistances to targeted therapies. Biochim. Et Biophys. Acta 2014, 1844, 909-916.
57. Iliuk, A. B., Arrington, J. V., Tao, W. A., Analytical challenges translating mass spectrometry-based phosphoproteomics from discovery to clinical applications. Electrophoresis 2014, in press.
58. de Graaf, E. L., Giansanti, P., Altelaar, A. F., Heck, A. J., Single step enrichment by Ti4+-IMAC and label free quantitation enables in-depth monitoring of phosphorylation dynamics with high reproducibility and temporal resolution. Mol. Cell. Proteomics 2014, 13, 2426-2434.
59. Montoya, A., Beltran, L., Casado, P., Rodriguez-Prados, J. C., Cutillas, P. R., Characterization of a TiO(2) enrichment method for label-free quantitative phosphoproteomics. Methods 2011, 54, 370-378.
60. Richardson, B. M., Soderblom, E. J., Thompson, J. W., Moseley, M. A., Automated, reproducible, titania-based phosphopeptide enrichment strategy for label-free quantitative phosphoproteomics. J. Biomol. Techn. 2013, 24, 8-16.
61. Sun, Z., Hamilton, K. L., Reardon, K. F., Evaluation of quantitative performance of sequential immobilized metal affinity chromatographic enrichment for phosphopeptides. Anal. Biochem. 2014, 445, 30-37.
62. Lawlor, K., Nazarian, A., Lacomis, L., Tempst, P., Villanueva, J., Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J. Proteome Res. 2009, 8, 1489-1503.
63. Rolland, D., Basrur, V., Conlon, K., Wolfe, T. et al., Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am. J. Pathol. 2014, 184, 1331-1342.
64. Wilkes, E., Casado, P., Cutillas, P. R., submitted.
65. Bateman, N. W., Goulding, S. P., Shulman, N. J., Gadok, A. K. et al., Maximizing peptide identification events in proteomic workflows using data-dependent acquisition (DDA). Mol. Cell. Proteomics 2014, 13, 329-338.
66. Chelius, D., Bondarenko, P. V., Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry. J. Proteome Res. 2002, 1, 317-323.
67. Cutillas, P. R., Geering, B., Waterfield, M. D., Vanhaesebroeck, B., Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line. Mol. Cell. Proteomics 2005, 4, 1038-1051.
68. Pinkse, M. W., Uitto, P. M., Hilhorst, M. J., Ooms, B., Heck, A. J., Selective isolation at the femtomole level of phosphopeptides from proteolytic digests using 2D-NanoLC-ESI-MS/MS and titanium oxide precolumns. Anal. Chem. 2004, 76, 3935-3943.
69. Beltran, L., Cutillas, P. R., Advances in phosphopeptide enrichment techniques for phosphoproteomics. Amino Acids 2012, 43, 1009-1024.
70. Li, Q. R., Ning, Z. B., Tang, J. S., Nie, S., Zeng, R., Effect of peptide-to-TiO2 beads ratio on phosphopeptide enrichment selectivity. J. Proteome Res. 2009, 8, 5375-5381.
71. Nilsson, T., Mann, M., Aebersold, R., Yates, J. R., 3rd et al., Mass spectrometry in high-throughput proteomics: ready for the big time. Nat. Methods 2010, 7, 681-685.
72. Conrads, T. P., Anderson, G. A., Veenstra, T. D., Pasa-Tolic, L., Smith, R. D., Utility of accurate mass tags for proteome-wide protein identification. Anal. Chem. 2000, 72, 3349-3354.
73. Cutillas, P. R., Vanhaesebroeck, B., Quantitative profile of five murine core proteomes using label-free functional proteomics. Mol. Cell. Proteomics 2007, 6, 1560-1573.
74. Tsou, C. C., Tsai, C. F., Tsui, Y. H., Sudhir, P. R. et al., IDEAL-Q, an automated tool for label-free quantitation analysis using an efficient peptide alignment approach and spectral data validation. Mol. Cell. Proteomics 2010, 9, 131-144.
75. Zhang, W., Zhang, J., Xu, C., Li, N. et al., LFQuant: a label-free fast quantitative analysis tool for high-resolution LC-MS/MS proteomics data. Proteomics 2012, 12, 3475-3484.
76. Casado, P., Cutillas, P. R., A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments. Mol. Cell. Proteomics 2011, 10, M110 003079.
77. Maurer, H. H., Liquid chromatography-mass spectrometry in forensic and clinical toxicology. J. Chromatogr. B 1998, 713, 3-25.
78. Nolen, B., Taylor, S., Ghosh, G., Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 2004, 15, 661-675.
79. Lienhard, G. E., Non-functional phosphorylations? Trends Biochem. Sci. 2008, 33, 351-352.
80. Landry, C. R., Levy, E. D., Michnick, S. W., Weak functional constraints on phosphoproteomes. Trends Genet. 2009, 25, 193-197.
81. Tan, C. S., Jorgensen, C., Linding, R., Roles of junk phosphorylation in modulating biomolecular association of phosphorylated proteins? Cell Cycle 2010, 9, 1276-1280.
82. Saez-Rodriguez, J., Alexopoulos, L. G., Epperlein, J., Samaga, R. et al., Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction. Mol. Systems Biol. 2009, 5, 331.
83. Saez-Rodriguez, J., Alexopoulos, L. G., Zhang, M., Morris, M. K. et al., Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer Res. 2011, 71, 5400-5411.
84. Linding, R., Jensen, L. J., Ostheimer, G. J., van Vugt, M. A. et al., Systematic discovery of in vivo phosphorylation networks. Cell 2007, 129, 1415-1426.
85. Horn, H., Schoof, E. M., Kim, J., Robin, X. et al., KinomeXplorer: an integrated platform for kinome biology studies. Nat. Methods 2014, 11, 603-604.
86. Casado, P., Rodriguez-Prados, J. C., Cosulich, S. C., Guichard, S. et al., Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci. Signal. 2013, 6, rs6.
87. Niepel, M., Hafner, M., Pace, E. A., Chung, M. et al., Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci. Signal. 2013, 6, ra84.
88. Casado, P., Bilanges, B., Rajeeve, V., Vanhaesebroeck, B., Cutillas, P. R., Environmental stress affects the activity of metabolic and growth factor signaling networks and induces autophagy markers in MCF7 breast cancer cells. Mol. Cell. Proteomics 2014, 13, 836-848.
89. Mertins, P., Yang, F., Liu, T., Mani, D. R. et al., Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol. Cell. Proteomics 2014, 13, 1690-1704.
90. Zhao, B., Hemann, M. T., Lauffenburger, D. A., Intratumor heterogeneity alters most effective drugs in designed combinations. Proc. Natl. Acad. Sci. USA 2014, 111, 10773-10778.
91. Renshaw, J., Taylor, K. R., Bishop, R., Valenti, M. et al., Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin. Cancer Res. 2013, 19, 5940-5951.
92. Strano-Rossi, S., Odoardi, S., Castrignano, E., Serpelloni, G., Chiarotti, M., Liquid chromatography-high resolution mass spectrometry (LC-HRMS) determination of stimulants, anorectic drugs and phosphodiesterase 5 inhibitors (PDE5I) in food supplements. J. Pharm. Biomed. Anal. 2014, doi: 10.1016/j.jpba.2014.06.011
93. Musenga, A., Cowan, D. A., Use of ultra-high pressure liquid chromatography coupled to high resolution mass spectrometry for fast screening in high throughput doping control. J. Chromatogr. A 2013, 1288, 82-95.